We usually think about a medicine in one simple timeline:
Manufactured → prescribed → taken → treated → done.
But biologically, the story doesn’t end there.
Once a drug leaves our body, its residues can enter sewage systems and eventually reach rivers, groundwater and other ecosystems. A 2025 review in Environmental Monitoring and Assessment highlights that pharmaceutical residues including antibiotics, hormones, NSAIDs and other drugs can persist in the environment because some are resistant to conventional degradation.
The traditional approach vs the modern approach
Traditional wastewater treatment often relies on filtration, adsorption, membranes, ozonation, oxidation and other physicochemical techniques. These can be useful, but pharmaceutical contaminants are chemically diverse and sometimes difficult or expensive to remove completely.
This is where biotechnology gives us a completely different perspective.
Instead of asking: “How do we physically remove this chemical?”
we can ask: “Can biology break it down?”
Enter bioremediation
Microorganisms such as bacteria, fungi and algae can transform, degrade or detoxify certain pharmaceutical pollutants. The interesting part is that these organisms don’t simply filter the contaminant they can potentially biologically transform the molecule itself into less harmful forms. The review discusses both indigenous microorganisms already present in contaminated environments and microorganisms introduced for remediation.
And this opens up a very biotech way of thinking: Microbiology + enzymology + environmental science + biotechnology = cleaner pharmaceutical ecosystems.
But is bioremediation the perfect solution?
Not yet, Microbial activity can be difficult to control, treatment can take time, high pollutant concentrations can reduce effectiveness, and engineered microorganisms raise additional safety and management questions.
That is why the modern approach isn’t simply “replace chemistry with microbes.” It is about combining technologies intelligently. Advanced wastewater treatment, microbial degradation and green pharmacy could work together from designing drugs that remain stable when needed therapeutically but are more readily degraded after excretion, to improving wastewater treatment before pharmaceutical residues reach natural ecosystems.
A new way to look at biotechnology
For me, this is one of the most interesting directions in biotechnology. We often associate biotech with vaccines, genetic engineering, diagnostics or drug development.But biotechnology can also ask a bigger question:
What happens to our biological products after they have done their job?The future of medicine may therefore not be just about developing a drug that works inside the human body.It could be about designing the entire life cycle of that drug from manufacturing and use to disposal and environmental degradation.
Because a truly sustainable medicine shouldn’t only be safe for the patient.
It should also be responsible toward the ecosystem that receives it afterward.
What do you thinkshould pharmaceutical companies consider the environmental fate of a drug while designing it, rather than only focusing on its therapeutic effect?
MBH/PS